Urinary Proteomics—a Tool for Biomarker Discovery

REFERENCES

• Muller GA, Muller CA, Dihazi H. Clinical proteomics—on the long way from bench to bedside. Nephrol Dial Transplant. 2007;22:1297–1300.
   PubMedGoogle Scholar
• Fliser D, Novak J, Thongboonkerd V, Argiles A, Jankowski V, Girolami MA, Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol. 2007;18:1057–1071.
   PubMed Web of Science ®Google Scholar
• Adachi J, Kumar C, Zhang Y, Olsen JV, Mann M. The human urinary proteome contains more then 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 2006;7:R80.
   PubMed Web of Science ®Google Scholar
• Hortin GL, Sviridov D. Diagnostic potential for urinary proteomics. Pharmacogenomics. 2007;8:237–255.
   PubMed Web of Science ®Google Scholar
• Kumar S, Tsai CJ, Nussinov R. Temperature range of thermodynamic stability for the native state of reversible two-state proteins. Biochemistry. 2003;42:4864–4873.
   PubMed Web of Science ®Google Scholar
• Pisitkun T, Johnstone R, Knepper MA. Discovery of urinary biomarkers. Mol Cell Proteomics. 2006;5:1760–1771.
   PubMed Web of Science ®Google Scholar
• Dihazi H, Muller G. Urinary proteomics: A tool to discover biomarkers of kidney diseases. Expert Rev Proteomics. 2007;4:39–50.
   PubMed Web of Science ®Google Scholar
• Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Natl Acad Sci USA. 2004;101:13368–13373.
   PubMed Web of Science ®Google Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics. Nature. 2003;422:198–207.
   PubMed Web of Science ®Google Scholar
• Hanash S. 2-D or not 2-D: Is there a future for 2-D gels in proteomics? Insights from the York proteomics meeting. Proteomics. 2001;1:635–637.
   PubMedGoogle Scholar
• Henzel WJ, Billeci TM, Stults JT, Wong SC, Grimley C, Watanabe C. Identifying proteins from two-dimensional gels by molecular mass searching of peptide fragments in protein sequence databases. Proc Natl Acad Sci USA. 1993;90: 5011–5015.
   PubMed Web of Science ®Google Scholar
• Vidal BC, Bonventre JV, Hong Hsu SI. Towards the application of proteomics in renal disease diagnosis. Clin Sci. 2005; 109:421–430.
   PubMed Web of Science ®Google Scholar
• Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int. 2005;67:2313–2320.
   PubMed Web of Science ®Google Scholar
• Park MR, Wang EH, Jin DC, Cha JH, Lee KH, Yang CW, Establishment of a 2-D human urinary proteomic map in IgA nephropathy. Proteomics. 2006;6:1066–1076.
   PubMed Web of Science ®Google Scholar
• Ngai HH, Sit WH, Jiang PP, Xu RJ, Wan JM, Thongboonkerd V. Serial changes in urinary proteome profile of membranous nephropathy: Implications for pathophysiology and biomarker discovery. J Proteome Res. 2006;5: 3038–3047.
   PubMedGoogle Scholar
• Ngai HH, Sit WH, Jiang PP, Thongboonkerd V, Wan JM. Markedly increased urinary preprohaptoglobin and haptoglobin in passive Heymann nephritis: A differential proteomics approach. J Proteome Res. 2007;6:3313–3320.
   PubMed Web of Science ®Google Scholar
• Shui H, Huang T, Ka S, Chen P, Lin Y, Chen A. Urinary proteome and potential biomarkers associated with serial pathogenesis steps of focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2008;23:176–185.
   PubMedGoogle Scholar
• Wittke S, Haubitz M, Walden M, Rohde F, Schwarz A, Mengel M, Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am J Transplant. 2005;5:2479–2488.
   PubMed Web of Science ®Google Scholar
• Clarke W, Silverman BC, Zhang Z, Chan DW, Klein AS, Molmenti EP. Characterization of renal allograft rejection by urinary proteomic analysis. Ann Surg. 2003;237: 660–664.
   PubMed Web of Science ®Google Scholar
• Schaub S, Wilkins JA, Antonovici M, Krokhin O, Weiler T, Rush D, Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant. 2005;5: 729–738.
   PubMed Web of Science ®Google Scholar
• O'Riordan E, Orlova TN, Podust VN, Chander PN, Yanagi S, Nakazato M, Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am J Transplant. 2007;7:930–940.
   PubMed Web of Science ®Google Scholar
• Quintana LF, Solé-Gonzalez A, Kalko SG, Bañon-Maneus E, Solé M, Diekmann F, Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol. 2009;20:428–435.
   PubMed Web of Science ®Google Scholar
• Nguyen MT, Devarajan P. Biomarkers for the early detection of acute kidney injury. Pediatr Nephrol. 2008;23: 2151–2157.
   PubMed Web of Science ®Google Scholar
• Zhou H, Pisitkun T, Aponte A, Yen PS, Hoffert JD, Yasuda H, Exosomal fetuin-A identified by proteomics: A novel urinary biomarker for detecting acute kidney injury. Kidney Int. 2006;70:1847–1857.
   PubMed Web of Science ®Google Scholar
• Pisitkun T, Shen RF, Knepper MA. Identification and proteomic profiling of exosomes in human urine. Proc Nat Acad Sci USA. 2004;101:13368–13373.
   PubMed Web of Science ®Google Scholar
• Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionization and neural-network analysis: Identification of key issues affecting potential clinical utility. Cancer Res. 2003;63: 6971–6983.
   PubMed Web of Science ®Google Scholar
• Pieper R, Gatlin CL, McGrath AM. Characterization of the human urinary proteome: A method for high-resolution display of urinary proteins on two-dimensional electrophoresis gels with a yield of nearly 1400 distinct protein spots. Proteomics. 2004;4:1159–1174.
   PubMed Web of Science ®Google Scholar
• Han WK, Alinani A, Wu CL, Michaelson D, Loda M, McGovern FJ, Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol. 2005;16:1126–1134.
   PubMed Web of Science ®Google Scholar
• Lichtenfels R, Dressler SP, Zobawa M, Recktenwald CV, Ackermann A, Atkins D, Systematic comparative protein expression profiling of clear cell renal cell carcinoma: A pilot study based on the separation of tissue specimen by two dimensional electrophoresis. Mol Cell Proteomics. 2009, September 14 [e-pub ahead of print].
   PubMedGoogle Scholar
• Vasudev NS, Sim S, Cairns DA, Ferguson RE, Craven RA, Stanley A, Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br J Cancer. 2009;101:1175–1182.
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol. 2001;158: 1491–1502.
   PubMed Web of Science ®Google Scholar
• Mueller J, Von Eggeling F, Driesch D, Schubert J, Melle C, Junker K. ProteinChip technology reveals distinctive protein expression profiles in the urine of bladder cancer patients. Eur Urol. 2005;47:885–893.
   PubMed Web of Science ®Google Scholar
• Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Discovery and validation of new protein biomarkers for urothelial cancer: A prospective analysis. Lancet Oncol. 2006;7:230–240.
   PubMed Web of Science ®Google Scholar
• Irmak S, Tilki D, Heukeshoven J, Oliveira-Ferrer L, Friedrich M, Huland H, Stage-dependent increase of orosomucoid and zinc-alpha2-glycoprotein in urinary bladder cancer. Proteomics. 2005;5:4296–4304.
   PubMed Web of Science ®Google Scholar
• Kageyama S, Isono T, Iwaki H, Wakabayashi Y, Okada Y, Kontani K, Identification by proteomic analysis of calreticulin as a marker for bladder cancer and evaluation of the diagnostic accuracy of its detection in urine. Clin Chem. 2004;50:857–866.
   PubMed Web of Science ®Google Scholar
• Iwaki H, Kageyama S, Isono T, Wakabayashi Y, Okada Y, Yoshimura K, Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, γ-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis. Cancer Sci. 2004;95:955–961.
   PubMed Web of Science ®Google Scholar
• Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder cancer associated glycoprotein signatures revealed by urinary proteomic profiling. J Proteome Res. 2007;6:2631–2639.
   PubMed Web of Science ®Google Scholar
• Celis JE, Rasmussen HH, Vorum H, Madsen P, Honore B, Wolf H, Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. J Urol. 1996;155: 2105–2112.
   PubMed Web of Science ®Google Scholar
• Kaiser T, Kamal H, Rank A, Kolb HJ, Holler E, Ganser A, Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:340–349.
   PubMed Web of Science ®Google Scholar
• Comte B, Franceschi C, Sadoulet MO, Silvy F, Lafitte D, Benkoel L, Detection of bile salt-dependent lipase, a 110 kDa pancreatic protein, in urines of healthy subjects. Kidney Int. 2006;69:1048–1055.
   PubMed Web of Science ®Google Scholar
• Polotsky VY, O'Donnell CP. Genomics of sleep-disordered breathing. Proc Am Thorac Soc. 2007;4:121–126.
   PubMedGoogle Scholar
• Weeks ME, Hariharan D, Lj Petronijevic, Radon TP, Whiteman HJ, Kocher HM, Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. Proc Am Thorac Soc. 2008;7–8:1047–1057.
   Google Scholar
• Tantipaiboonwong P, Sinchaikul S, Sriyam S, Phutrakul S, Chen ST. Different techniques for urinary protein analysis of normal and lung cancer patients. Proteomics. 2005;5: 1140–1149.
   PubMed Web of Science ®Google Scholar
• Meier M, Kaiser T, Herrmann A, Knueppel S, Hillmann M, Koester P, Identification of urinary protein pattern in type 1 diabetic adolescents with early diabetic nephropathy by a novel combined proteome analysis. J Diabetes Complications. 2005;19:223–232.
   PubMed Web of Science ®Google Scholar
• Mischak H, Kaiser T, Walden M, Hillmann M, Wittke S, Herrmann A, Proteomic analysis for the assessment of diabetic renal damage in humans. Clin Sci (Lond). 2004;107:485–495.
   PubMed Web of Science ®Google Scholar
• Sharma K, Lee S, Han S, Lee S, Francos B, McCue P, Two-dimensional fluorescence difference gel electrophoresis analysis of the urine proteome in human diabetic nephropathy. Proteomics. 2005;5:2648–2655.
   PubMed Web of Science ®Google Scholar
• Dihazi H, Muller G, Lindner S, Meyer M, Asif AR, Oellerich M, Characterisation of diabetic nephropathy by urinary proteomic analysis: Identification of a precessed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin Chem. 2007;53:1636–1645.
   PubMed Web of Science ®Google Scholar
• Rao PV, Lu X, Standley M, Pattee P, Neelima G, Girisesh G, Proteomic identification of urinary biomarkers of diabetic nephropathy. Diabetes Care. 2007;30: 629–637.
   PubMed Web of Science ®Google Scholar
• Otu HH, Can H, Spentzos D, Nelson RG, Hanson RL, Looker HC, Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care. 2007;30:638–643.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Birmingham DJ, Nagaraja HN, Yu CY, Hebert LA. Biomarker discovery in human SLE nephritis. Bull NYU Hosp Jt Dis. 2007;65:187–193.
   PubMedGoogle Scholar
• Suzuki M, Ross GF, Wiers K, Nelson S, Bennett M, Passo MH, Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr Nephrol. 2007;22: 2047–2057.
   PubMed Web of Science ®Google Scholar
• Mosley KF, Tam WK, Edwards RJ, Crozier J, Pusey CD, Lightstone L. Urinary proteomic profiles distinguish between active and inactive lupus nephritis. Rheumatology. 2006;45: 1497–1504.
   PubMed Web of Science ®Google Scholar
• Decramer S, Uulm Rbig P, Wittke S, Mischak H, Bascands JL, Schanstra JP. Identification of urinary biomarkers by proteomics in newborns: Use in obstructive nephropathy. Contrib Nephrol. 2008;160:127–141.
   PubMed Web of Science ®Google Scholar
• Zimmerli LU, Schiffer E, Zurbig P, Good DM, Kellmann M, Mouis L, Urinary proteomic biomarkers in coronary artery disease. Mol Cell Proteomics. 2008;7: 290–298.
   PubMed Web of Science ®Google Scholar
• Buhimschi IA, Zhao G, Funai EF, Harris N, Sasson IE, Bernstein IM, Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol. 2008;199:551. e1–551.e16.
   PubMed Web of Science ®Google Scholar
• Rocchetti MT, Centra M, Papale M, Bortone G, Palermo C, Centonze D, Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy. Proteomics. 2008;8:206–216.
   PubMed Web of Science ®Google Scholar
• Woroniecki RP, Orlova TN, Mendelev N, Shatat IF, Hailpern SM, Kaskel FJ, Urinary proteome of steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome of childhood. Am J Nephrol. 2006;26:258–267.
   PubMed Web of Science ®Google Scholar
• Khurana M, Traum AZ, Aivado M, Wells M, Guerrero M, Grall F. Urine proteomic profiling of pediatric nephrotic syndrome. Pediatr Nephrol. 2006;21:1257–1265.
   PubMedGoogle Scholar
• Theodorescu D, Schiffer E, Bauer H, Douwes F, Eichhorn F, Polley R, Discovery and validation of urinary biomarkers for prostate cancer. Proteomics Clin Appl. 2008;2: 556–570.
   PubMed Web of Science ®Google Scholar
• Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res. 2006;12:431–441.
   Google Scholar
• Coon JJ, Zürbig P, Dakna M, Dominiczak AF, Decramer S, Fliser D, CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl. 2008;2:964–973.
   PubMed Web of Science ®Google Scholar
• Dihazi H, Müller GA. Urinary proteomics: A tool to discover biomarkers of kidney diseases. Expert Rev Proteomics. 2007;4:39–50.
   PubMed Web of Science ®Google Scholar
• Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, Dominicsak A, Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics Clin Appl. 2007;1:148–156.
   PubMed Web of Science ®Google Scholar
• Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054–1061.
   PubMed Web of Science ®Google Scholar
• Vlahou A, Schanstra J, Frokiaer J, El Nahas M, Spasovski G, Mischak H, Establishment of a European network for urine and kidney proteomics. J Proteomics. 2008;71: 490–492.
   PubMed Web of Science ®Google Scholar